Clinical trials: Renal Osteodystrophy
Chronic Kidney Diseases, Osteodystrophy
Effect of Allopurinol on Markers of Mineral and Bone Metabolism
Hyperuricemia is a common condition in patients with chronic kidney disease (CKD) in the glomerular filtration rate. Recently, it has been suggested that uric acid is related to a mineral and bone disease of CKD (CKD-MBD) since…
- Conditions
- Chronic Kidney Diseases, Osteodystrophy, Uric Acid Concentration, Serum, Quantitative Trait Locus 7
- Trial name
- NCT05601271
- Testing
- Allopurinol
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- University of Sao Paulo General Hospital
Renal Osteodystrophy
Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD
The proposed 6 month pilot and feasibility randomized trial will evaluate LMMS as an anabolic stimulus to bone in 30 adults on maintenance hemodialysis.
- Trial name
- NCT00364234
- Testing
- Low magnitude mechanical stimuli
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hyperphosphatemia
The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients
Elevated phosphorus levels are a common problem in dialysis patients. However, it is associated with an increase in death and hospitalizations.
- Trial name
- NCT00316472
- Testing
- Niacinamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Renal Transplant Osteodystrophy
Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
Patients with kidney failure have underlying bone disease at the time of transplant. Fractures of various bones can be as high as 22%. Medication required for the transplant plays a role in bone loss.
- Trial name
- NCT00266708
- Testing
- Risedronate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in the normal clinical setting and according…
- Trial name
- NCT01149291
- Where
- 22 sites in Turkey (Türkiye)
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease, Vascular Calcification
Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease
Randomized placebo-controlled double-blinded interventional trial to investigate the effect of oral magnesium supplementation on vascular calcification in subjects with chronic kidney disease.
- Conditions
- Chronic Kidney Disease, Vascular Calcification, Uremic Osteodystrophy
- Trial name
- MagiCal-CKD (NCT02542319)
- Testing
- Mablet 360 mg
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 148 people
- Sponsor
- Nordsjaellands Hospital
Hyperphosphatemia
The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
Hyperphosphatemia is common in the peritoneal dialysis population. Current strategies are insufficient to optimize phosphorus control.
- Trial name
- NCT00508885
- Testing
- Niacinamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Chronic Kidney Disease, End Stage Kidney Disease
Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease
Kidney disease patients have a variety of bone disorders that result in bone loss and fractures. The mechanisms of these bone disorders are not clear but may be related to abnormal modification of a bone protein known as…
- Conditions
- Chronic Kidney Disease, End Stage Kidney Disease, Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy
- Trial name
- NCT03626246
- Testing
- Kidney disease
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Renal Osteodystrophy
Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD)
Bone and mineral disease is a key problem in patients with kidney disease. The available clinical parameters are non-specific, unproven for the assessment of the bone metabolism and do not reflect the complexity and diversity of…
- Trial name
- BoneX (NCT02556216)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Hannover Medical School
Osteoporosis, Renal Osteodystrophy
The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients
This is a Phase 2 Multi-Center Clinical Trial (safety and effectiveness trial) in 60 patients (40 denosumab; 20 placebo) who have had a kidney transplant for 12-months or longer with more than 30% of kidney function.
- Conditions
- Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
- Trial name
- ProliaKTx (NCT03960554)
- Testing
- Denosumab Inj 60 mg/ml
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Thomas Nickolas, MD MS
Chronic Kidney Disease, End Stage Renal Disease
Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia
Patients with chronic kidney disease (CKD) and those with end-stage renal disease (ESRD) undergoing renal replacement therapies show elevated serum phosphate levels which predispose them to cardiovascular calcifications and high…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Hyperphosphatemia, Renal Osteodystrophy
- Trial name
- NCT00374712
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Secondary Hyperparathyroidism, Renal Osteodystrophy
Regulation of Bone Formation in Renal Osteodystrophy
To examine the effects of two types of active vitamin D (calcitriol and doxercalciferol) and two phosphate binders (sevelamer and calcium carbonate) on the bone disease and blood tests of children with kidney failure
- Trial name
- NCT00560300
- Testing
- 1 alpha D2, 1,25 dihydroxy vitamin D3, Sevelamer HCl
- Volunteers
- 61 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Restless Leg Disorder, Renal Disease Bone
Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease
Restless leg syndrome (RLS) is sleep disorder characterized by an unpleasant feeling in the lower limbs, which can be accompanied by paresthesias, and need for urgent movement of the legs.
- Conditions
- Restless Leg Disorder, Renal Disease Bone, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- RLS (NCT03063190)
- Testing
- Vitamin D
- Where
- Brazil
- Sponsor
- University of Sao Paulo General Hospital
Bone Mineralization Defect
How Bone is Made in Children Receiving Dialysis
The study outlined is designed to measure and to determine whether the combined use of vitamin D2 (ergocalciferoI) and 1-alpha-hydroxyvitamin D2 (doxercalciferol)) or doxercalciferol alone will correct the mineralization defect…
- Trial name
- NCT01799317
- Testing
- Vitamin D2
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of California, Los Angeles
Renal Insufficiency, Chronic, Renal Osteodystrophy
Kidney Yin/Yang Replenishment on Patients With Renal Osteodystrophy
Patients with serious chronic renal insufficiency usually develop secondary osteoporosis or bone loss, especially those with chronic dialysis, and the degree of bone loss is corrected with decrease of renal function.
- Trial name
- NCT01665651
- Testing
- Yougui granules, Zuogui granules
- Where
- 3 sites in China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bing Shu
Chronic Kidney Disease, Renal Osteodystrophy
Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients
Sclerostin, the product of the SOST gene, located on chromosome 17, locus q11.2 in humans, was originally believed to be a non-classical Bone morphogenetic protein (BMP) antagonist.Sclerostin was recently identified as a…
- Conditions
- Chronic Kidney Disease, Renal Osteodystrophy, Left Ventricular Hypertrophy
- Trial name
- NCT01382966
- Where
- Turkey (Türkiye)
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- RFM Renal Treatment Services
Kidney Transplantation, Vitamin D Deficiency
Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients
The purpose of the study is to evaluate the effects of Cholecalciferol (Vitamin D3) substitution on the posttransplant outcome (glomerular filtration rate as well as serum creatinine levels, number of acute rejection episodes…
- Conditions
- Kidney Transplantation, Vitamin D Deficiency, Renal Osteodystrophy
- Trial name
- VITA-D (NCT00752401)
- Testing
- Cholecalciferol
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Hypocalcemia, Pseudohypoparathyroidism
Studies of States With Resistance to Vitamin D and Parathyroid Hormone
Patients with confirmed or suspected states with resistance to vitamin D or parathyroid hormone (PTH) will be admitted for diagnosis, treatment review with suggestions for modifications to the current or new treatment and for…
- Conditions
- Hypocalcemia, Pseudohypoparathyroidism, Osteomalacia, Rickets
- Trial name
- NCT00001242
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Secondary Hyperparathyroidism, Chronic Kidney Disease
Treatment of Secondary Hyperparathyroidism in the Uremic Patient
The purpose of this study is to compare alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease, Vitamin D Deficiency
- Trial name
- NCT00469599
- Testing
- paricalcitol, alfacalcidol
- Where
- 8 sites in Denmark
- Volunteers
- 86 people
- Sponsor
- Zealand University Hospital
Renal Osteodystrophy
Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
The majority of patients with moderate to severe chronic kidney disease (CKD) (stages 3 and 4) develop secondary hyperparathyroidism (2°HPT), but the optimal therapy to control hyperparathyroidism in this group is unknown.
- Trial name
- NCT00285467
- Testing
- doxercalciferol, Cholecalciferol
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Indiana University